Skip to Content
Print Share

Generic Jentadueto XR Availability

See also: Generic Jentadueto

Jentadueto XR is a brand name of linagliptin/metformin, approved by the FDA in the following formulation(s):

JENTADUETO XR (linagliptin; metformin hydrochloride - tablet, extended release;oral)

Has a generic version of Jentadueto XR been approved?

No. There is currently no therapeutically equivalent version of Jentadueto XR available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Jentadueto XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
    Patent 6,488,962
    Issued: December 3, 2002
    Inventor(s): Bret; Berner & Jenny; Louie-Helm
    Assignee(s): DepoMed, Inc.

    The retention of oral drug dosage forms in the stomach is improved by using swellable dosage forms that are shaped in a manner that will prevent them from inadvertently passing through the pylorus as a result of being in a particular orientation. The planar projection of the shape is one that has two orthogonal axes of different lengths, the longer being short enough to permit easy swallowing prior to swelling while the shorter is long enough within one-half hour of swelling to prevent passage through the pylorus.

    Patent expiration dates:

    • June 20, 2020
      ✓ 
      Drug product
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent 6,890,898
    Issued: May 10, 2005
    Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
    Assignee(s): Trustees of Tufts College 1149336 Ontario Inc. New England Medical Center Hospitals, Inc.

    The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.

    Patent expiration dates:

    • February 2, 2019
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent 7,078,381
    Issued: July 18, 2006
    Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
    Assignee(s): Trustees of Tufts College

    The present invention provides methods and compositions for modifying glucose metabolism and treating Type II diabetes in an animal, along with modifying metabolism of a peptide hormone in an animal. Compositions disclosed herein comprise one or more peptides and/or peptide analogs which include a functional group that reacts with an active site residue of a protease.

    Patent expiration dates:

    • February 2, 2019
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent 7,407,955
    Issued: August 5, 2008
    Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf R. H. & Tadayyon; Mohammad
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co., KG

    The present invention relates to substituted xanthines of general formula wherein R1 to R3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

    Patent expiration dates:

    • May 2, 2025
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Method of regulating glucose metabolism, and reagents related thereto
    Patent 7,459,428
    Issued: December 2, 2008
    Inventor(s): Bachovchin; William W. & Plaut; Andrew G. & Drucker; Daniel
    Assignee(s): Trustees of Tufts College New England Medical Center Hospitals, Inc. 1149336 Ontario, Inc.

    One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of dipeptidylpeptidase IV or a pharmaceutically acceptable salt thereof in an amount sufficient to treat Type II diabetes of the animal.

    Patent expiration dates:

    • February 2, 2019
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent 8,119,648
    Issued: February 21, 2012
    Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG

    The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

    Patent expiration dates:

    • August 12, 2023
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
  • 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
    Patent 8,178,541
    Issued: May 15, 2012
    Inventor(s): Himmelsbach; Frank & Langkopf; Elke & Eckhardt; Matthias & Mark; Michael & Maier; Roland & Lotz; Ralf & Tadayyon; Mohammad
    Assignee(s): Boehringer Ingelheim Pharma GmbH & Co. KG

    The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

    Patent expiration dates:

    • August 12, 2023
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA
      ✓ 
      Drug product
  • Uses of DPP-IV inhibitors
    Patent 8,673,927
    Issued: March 18, 2014
    Assignee(s): Boehringer Ingelheim International GmbH

    The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

    Patent expiration dates:

    • May 4, 2027
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
  • Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
    Patent 8,883,805
    Issued: November 11, 2014
    Assignee(s): Boehringer Ingelheim International GmbH

    The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.

    Patent expiration dates:

    • November 26, 2025
      ✓ 
      Drug product
  • DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
    Patent 9,155,705
    Issued: October 13, 2015
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

    Patent expiration dates:

    • May 21, 2030
      ✓ 
      Drug product
  • Uses of DPP IV inhibitors
    Patent 9,173,859
    Issued: November 3, 2015
    Assignee(s): Boehringer Ingelheim International GmbH

    The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.

    Patent expiration dates:

    • May 4, 2027
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
      ✓ 
      Drug product
  • DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
    Patent 9,415,016
    Issued: August 16, 2016
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

    Patent expiration dates:

    • April 2, 2029
      ✓ 
      Drug product
  • Pharmaceutical composition and uses thereof
    Patent 9,555,001
    Issued: January 31, 2017
    Assignee(s): Boehringer Ingelheim International GmbH

    The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and/or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

    Patent expiration dates:

    • March 6, 2033
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
      ✓ 
      Drug product
    • March 6, 2033
      ✓ 
      Patent use: METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN
      ✓ 
      Drug product
Add to My Med List

More about Jentadueto XR (linagliptin / metformin)

Consumer resources

Other brands: Jentadueto

Professional resources

Related treatment guides

Glossary
TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Drugs.com Mobile Apps

The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Available for Android and iOS devices.

Explore Apps
Hide